The Latest Cardiac and Vascular News
SANTA CLARA, Calif., Oct. 8, 2023 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced 6-month results of the REBALANCE-HF randomized, blinded feasibility trial of the Splanchnic Ablation for Volume Management (SAVM) procedure for heart failure […]
SANTA CLARA, Calif., March 22, 2023 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced positive 6-month results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF. The latest data is consistent with prior […]
Late-breaking results presented at the European Society of Cardiology’s Heart Failure Association annual conference and simultaneously published online in the European Journal of Heart Failure SANTA CLARA, Calif., May 23, 2022 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root […]
SANTA CLARA, Calif., Feb. 15, 2022 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of Brian Farley to the company’s Board of Directors. With three decades of experience leading medtech companies, Mr. Farley […]
Seasoned medical device executive prepares for commercialization of innovative heart failure therapy SANTA CLARA, Calif., July 21, 2021 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of seasoned medical device […]
Satera™ Ablation System demonstrates success as a frontline treatment of heart failure NEW YORK, Oct. 9, 2020 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing one of the root causes of heart failure, today announced positive interim results from their […]
